Prognostic value of prognostic nutritional index and its variations in advanced non‐small‐cell lung cancer patients treated with anlotinib monotherapy

BACKGROUND: Anlotinib is a third‐line or further therapy for advanced non‐small‐cell lung cancer (NSCLC). However, the lack of simple biomarkers to predict the curative effect of anlotinib creates significant unmet needs in exploring the markers. This study aimed to explore the relationship between...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Tian, Liang, Gaofeng, Xiang, Zhenfei, He, Jinxian, Xu, Xiaoyu, Tang, Mengqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993602/
https://www.ncbi.nlm.nih.gov/pubmed/35179795
http://dx.doi.org/10.1002/jcla.24300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993602/
https://www.ncbi.nlm.nih.gov/pubmed/35179795
http://dx.doi.org/10.1002/jcla.24300

Ejemplares similares